105 related articles for article (PubMed ID: 9892992)
21. Identification and isolation of melanoma-associated antigens with monoclonal antibodies.
Ross AH; Mitchell KF; Steplewski Z; Koprowski H
Hybridoma; 1982; 1(4):413-21. PubMed ID: 6765324
[TBL] [Abstract][Full Text] [Related]
22. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
[TBL] [Abstract][Full Text] [Related]
23. Effect of bacillus Calmette-Guerin immunotherapy on tumor antigen-induced lymphocyte-stimulated protein synthesis in melanoma patients.
Roth JA; Golub SH; Holmes EC; Morton DL
Surgery; 1975 Jul; 78(1):66-75. PubMed ID: 1138401
[TBL] [Abstract][Full Text] [Related]
24. In vitro immunization of human B lymphocytes with cultured melanoma cells (SK-MEL 28).
Zhang XM; Borrebaeck CA
Hum Antibodies Hybridomas; 1990; 1(1):42-6. PubMed ID: 1966473
[TBL] [Abstract][Full Text] [Related]
25. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
26. Cell activation influences cell staining kinetics.
Sunray M; Deutsch M; Kaufman M; Tirosh R; Weinreb A; Rachmani H
Spectrochim Acta A Mol Biomol Spectrosc; 1997 Sep; 53A(10):1645-53. PubMed ID: 9358654
[TBL] [Abstract][Full Text] [Related]
27. [Response of human lymphocytes to phytohemagglutinin (PHA) as measured by fluorescence polarization technique--differences between malignant conditions and benign or healthy conditions].
Tenzaki T; Ishiguro T
Nihon Gan Chiryo Gakkai Shi; 1989 Apr; 24(4):817-25. PubMed ID: 2778375
[TBL] [Abstract][Full Text] [Related]
28. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
[TBL] [Abstract][Full Text] [Related]
29. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen.
Sun Y; Song M; Stevanović S; Jankowiak C; Paschen A; Rammensee HG; Schadendorf D
Int J Cancer; 2000 Aug; 87(3):399-404. PubMed ID: 10897046
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
31. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
32. Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes.
Arienti F; Sulé-Suso J; Melani C; Maccalli C; Belli F; Illeni MT; Anichini A; Cascinelli N; Colombo MP; Parmiani G
Hum Gene Ther; 1994 Sep; 5(9):1139-50. PubMed ID: 7833372
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of mitogen-induced changes in intracellular fluorescein fluorescence polarization of human peripheral blood lymphocytes by colchicine, vinblastine and cytochalasin B.
Eisenthal A; Marder O; Lifschitz-Mercer B; Skornick Y; Tirosh R; Weinreb A; Deutsch M
Cell Struct Funct; 1996 Jun; 21(3):159-66. PubMed ID: 8853552
[TBL] [Abstract][Full Text] [Related]
34. Structure and epitope specificity of human melanoma-associated oncofetal antigen gp87 analyzed with monoclonal antibodies.
Liao SK; Leung WC; Kanamaru T
J Dermatol; 1985 Apr; 12(2):117-28. PubMed ID: 2411774
[No Abstract] [Full Text] [Related]
35. Purification and partial characterization of a shed 66 kDa melanoma-associated antigen identified by autologous antibody.
Vlock DR; Aul DJ; Toporowicz A; McCoy JP; Brown WE
Biochim Biophys Acta; 1991 Oct; 1080(1):1-10. PubMed ID: 1932077
[TBL] [Abstract][Full Text] [Related]
36. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy.
Kawakami Y; Rosenberg SA
Int Rev Immunol; 1997; 14(2-3):173-92. PubMed ID: 9131386
[TBL] [Abstract][Full Text] [Related]
37. Melanoma vaccines: the paradox of T cell activation without clinical response.
Nielsen MB; Marincola FM
Cancer Chemother Pharmacol; 2000; 46 Suppl():S62-6. PubMed ID: 10950150
[TBL] [Abstract][Full Text] [Related]
38. Indication that intracellular fluorescence polarization of T lymphocytes is cell cycle dependent.
Zurgil N; Deutsch M; Tirosh R; Brodie C
Cell Struct Funct; 1996 Aug; 21(4):271-6. PubMed ID: 8906363
[TBL] [Abstract][Full Text] [Related]
39. Tumour specificity of the SCM test for cancer diagnosis.
Chaitchik S; Asher O; Deutsch M; Weinreb A
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1165-70. PubMed ID: 2416568
[TBL] [Abstract][Full Text] [Related]
40. Analysis of early lymphocyte activation events by fluorescence polarization flow cytometry.
Dimitropoulos K; Rolland JM; Nairn RC
Immunol Cell Biol; 1988 Aug; 66 ( Pt 4)():253-60. PubMed ID: 3155329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
